AnalystsLeland GershellLeland Gershell's Stock Forecasts
AnalystsLeland Gershell
Analyst Ranking
Top 4%
#163 out of 5346 analysts
Average Return
+29.02%
Win Rate
51%87 out of 171
Risk vs Reward
Poor
Good
Leland Gershell's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Soleno Therapeutics IncSLNO | +1,687.66% | $2.35 | $42.01 | 2023-03-24 - 2024-03-22 | Buy |
Soleno Therapeutics IncSLNO | +978.37% | $4.90 | $52.84 | 2023-09-15 - 2024-09-13 | Buy |
Soleno Therapeutics IncSLNO | +718.29% | $5.03 | $41.16 | 2023-05-25 - 2024-05-24 | Buy |
Climb Bio IncCLYM | +658.99% | $1.39 | $10.55 | 2025-06-06 - 2026-06-05 | Buy |
Urogen Pharma LtdURGN | +430.80% | $5.00 | $26.54 | 2025-06-03 - 2026-06-02 | Buy |
Leland Gershell Analyst Color
Get additional color on Leland Gershell's coverage of popular stocks
Leland Gershell's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Trevi Therapeutics IncTRVI | 5 | Buy | $25.00 | +35.06% | Maintains | 3 days ago |
Biomarin Pharmaceutical IncBMRN | 5 | Buy | $97.00 | +52.01% | Maintains | 3 days ago |
Ligand Pharmaceuticals IncLGND | 3 | Buy | $326.00 | +11.21% | Reiterates | 7 days ago |
Argenx SeARGX | 9 | Buy | $1,037.00 | +19.88% | Maintains | 17 days ago |
Palisade Bio IncPALI | 1 | Buy | $8.00 | +279.15% | Initiates Coverage On | 18 days ago |
Urogen Pharma LtdURGN | 12 | Buy | $50.00 | +6.47% | Maintains | 25 days ago |
Crinetics Pharmaceuticals IncCRNX | 10 | Hold | N/A | N/A | Downgrades | a month ago |
Protara Therapeutics IncTARA | 4 | Buy | $28.00 | +579.61% | Maintains | 3 months ago |
Veru IncVERU | 9 | Buy | $24.00 | +930.04% | Maintains | 3 months ago |
Climb Bio IncCLYM | 2 | Buy | $18.00 | +28.57% | Maintains | 4 months ago |
Soleno Therapeutics IncSLNO | 10 | Buy | $80.00 | +50.91% | Maintains | 5 months ago |
Engene Therapeutics IncENGN | 4 | Buy | $30.00 | +1,566.67% | Maintains | 5 months ago |
Ocugen IncOCGN | 1 | Buy | $10.00 | +681.25% | Initiates Coverage On | 5 months ago |
Dianthus Therapeutics IncDNTH | 3 | Buy | $145.00 | +33.13% | Maintains | 5 months ago |
Calcimedica IncCALC | 6 | Buy | $10.00 | +1,353.49% | Maintains | 5 months ago |
Aardvark Therapeutics IncAARD | 2 | Buy | $21.00 | +165.82% | Maintains | 5 months ago |
Ascendis Pharma AASND | 12 | Buy | $262.00 | +2.58% | Maintains | 6 months ago |
Spruce Biosciences IncSPRB | 1 | Buy | $283.00 | +503.80% | Initiates Coverage On | 8 months ago |
Capricor Therapeutics IncCAPR | 6 | Buy | $54.00 | +1,220.29% | Maintains | 8 months ago |
Xeris Biopharma Holdings IncXERS | 6 | Buy | $18.00 | +126.99% | Maintains | 9 months ago |
Viridian Therapeutics IncVRDN | 7 | Buy | $36.00 | +52.61% | Maintains | 10 months ago |
Tectonic Therapeutic IncTECX | 1 | Buy | $80.00 | +158.23% | Initiates Coverage On | a year ago |
Bridgebio Pharma IncBBIO | 3 | Buy | $61.00 | N/A | Maintains | a year ago |
Alnylam Pharmaceuticals IncALNY | 6 | Buy | $490.00 | N/A | Upgrades | a year ago |
Lexeo Therapeutics IncLXEO | 1 | Buy | $20.00 | N/A | Initiates Coverage On | a year ago |
Rhythm Pharmaceuticals IncRYTM | 2 | Buy | $110.00 | N/A | Maintains | a year ago |
Quince Therapeutics IncQNCX | 1 | Buy | $2,000.00 | N/A | Initiates Coverage On | a year ago |
Essa Pharma IncEPIX | 2 | Hold | N/A | N/A | Downgrades | 2 years ago |
Immunovant IncIMVT | 3 | Buy | $53.00 | N/A | Maintains | 2 years ago |
Sab Biotherapeutics IncSABS | 2 | Buy | $12.00 | N/A | Reiterates | 2 years ago |
Nucana PLCNCNA | 8 | Buy | $5,000.00 | N/A | Maintains | 2 years ago |
Lumos Pharma IncLUMO | 5 | Buy | $13.00 | N/A | Maintains | 2 years ago |
Catalyst Pharmaceuticals IncCPRX | 3 | Buy | $29.00 | N/A | Reiterates | 2 years ago |
Avalo Therapeutics IncAVTX | 2 | Buy | $35.00 | N/A | Upgrades | 2 years ago |
Cue Biopharma IncCUE | 1 | Buy | $300.00 | N/A | Maintains | 2 years ago |
Pds Biotechnology CorpPDSB | 3 | Buy | $20.00 | N/A | Maintains | 3 years ago |
Milestone Pharmaceuticals IncMIST | 3 | Buy | $13.00 | N/A | Maintains | 3 years ago |
X4 Pharmaceuticals IncXFOR | 1 | Buy | $120.00 | N/A | Maintains | 3 years ago |
Clene IncCLNN | 1 | Hold | N/A | N/A | Downgrades | 4 years ago |
Plx Pharma IncPLXPQ | 2 | Hold | N/A | N/A | Downgrades | 4 years ago |
Horizon Therapeutics Public Ltd CoHZNP | 1 | Buy | $140.00 | N/A | Initiates Coverage On | 4 years ago |
Grace Therapeutics IncGRCE | 3 | Buy | $36.00 | N/A | Initiates Coverage On | 5 years ago |
Opiant Pharmaceuticals IncOPNT | 1 | Buy | $42.00 | N/A | Initiates Coverage On | 5 years ago |
Clarus Therapeutics Holdings IncCRXTQ | 1 | Buy | $12.00 | N/A | Initiates Coverage On | 5 years ago |
Windtree Therapeutics IncWINT | 1 | Buy | $7,200.00 | N/A | Initiates Coverage On | 5 years ago |
Trevena IncTRVN | 2 | Hold | N/A | N/A | Initiates Coverage On | 5 years ago |
Teva Pharmaceutical Industries LtdTEVA | 1 | Hold | N/A | N/A | Initiates Coverage On | 6 years ago |
Casi Pharmaceuticals IncCASI | 1 | Buy | $50.00 | N/A | Initiates Coverage On | 6 years ago |
Vaccinex IncVCNX | 2 | Buy | $1,470.00 | N/A | Maintains | 6 years ago |
Fresh Tracks Therapeutics IncFRTX | 1 | Buy | $5.00 | N/A | Initiates Coverage On | 6 years ago |
Acceleron Pharma IncXLRN | 1 | Buy | $112.00 | N/A | Maintains | 6 years ago |
Epizyme IncEPZM | 1 | Hold | $16.00 | N/A | Downgrades | 6 years ago |
Amarin Corp PLCAMRN | 5 | Hold | N/A | N/A | Upgrades | 6 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.